‘FDA should withdraw ANDAs’ says expert

21 Oct 2019

CPhI Worldwide's Annual Report suggests repeat offenders of regulatory infringements should be barred from importing into the US.

CPhI Worldwide – the world’s largest pharma event taking place in Frankfurt (5th-7th November 2019) – has released the first part of its eponymous 2019 Annual Report. Experts Bikash Chatterjee, President and Chief Science Officer at Pharmtech Associates and Girish Malhotra, President of EPCOT International discuss how new technologies can revolutionise manufacturing, but warn that regulators must change to prevent hindering future innovation.

‘FDA should withdraw ANDAs’ says expert

Bikash Chatterjee forecasts a positive outlook for the medium and long-term future of the industry - Pharma 4.0, the Internet of Things (IoT), and Artificial Intelligence (AI) could ultimately deliver huge shifts in how we discover and develop medicines, even if the short-term applications may not bring the results people are striving for.

“There is no doubt we will see broader adoption of IoT on the shop floor and in the distribution portion of the supply chain in the short term. The biggest impact operationally, I believe, will be seen in the clinical trial management stage of the drug development lifecycle, over the next 5 years. During the next decade, however, AI could transform molecular selection and design,” commented Chatterjee.

Despite the call for these advances, Chatterjee emphasises that such improvements within the industry will not come about unless they are used in the right way, and address the right questions. He forewarns: “The focus on technology in the absence of understanding the basic question to be answered can derail a cross-functional initiative in the blink of an eye.” Chatterjee also calls for AI companies and pharmaceutical companies to gain a better understanding of each other’s fields to expedite the process of disruptive technology adoption.

“The challenge with anything new in our industry is that the organisations selling into life sciences don’t know drug development, and the drug sponsors interested in AI don’t really understand AI, so they cannot direct the solution provider very effectively. As this knowledge gap dissipates through experience on both sides, more effective pilot projects and solutions will be developed and brought to term,” says Chatterjee.

Moving into the longer-term future, Chatterjee envisages AI being used to deliver significant changes in therapies by 2040, when ‘it will be standard practice in the design of drug therapies, their processes and in the treatment of disease’. He predicts that ultimately this will mean personalizing dosing and drugs regimens designed around each patient’s genetic markers and circumstances.

Malhotra explores the cost of manufacturing globally and the still high levels of regulatory infringements, postulating that regulators should use powers to remove ANDAs for repeat offenders. “With FDA being short staffed, even the use of ‘risk-based inspections’ may be insufficient to catch less than quality/cGMP producers,” speculated Malhotra. He adds: “Repeated non-compliance to FDA’s requirements and guidelines should be a cause to forbid shipments to the US.”

In addition, he suggests a 90-day approval process, which will necessitate that companies filing applications have complete command of every facet of manufacturing, product quality, and labeling.

Taking this a step further, he also advocates enforcing mandatory deposits (circa $200,000) for first deviation from FDA’s expectations, with forfeiture of the deposit and, ultimately, being barred from importing into the US should further problems occur.

Fundamental to Malhotra’s regulatory proposals is the proposition that governing bodies should stick to enforcement - not preach to the market on how best to implement manufacturing processes. He added: “Pharma has not explored increased profitability through continued process improvements and my conjecture is that the regulators are the obstacle to this. The FDA should refrain from suggesting to companies what types of manufacturing processes (batch or continuous) they need or practice, instead they should concentrate on helping ensure manufacturing processes are repeatable using continuous improvement principles.”

CPhI Brand Director Europe, Orhan Caglayan, commented: “The CPhI Annual Report highlights the key issues and trends affecting the industry. Our experts explore the benefits of streamlined regulations and how technology could deliver tremendous improvements across the supply chain. Significantly, this year is also CPhI Worldwide’s 30th anniversary, which provides us with an opportunity to reflect on both how far the industry has come during this time, as well as where it is heading in the years to follow. With over 45,000 executives attending, our event is designed to help meet new partners and drive forward innovation. By bringing the supply chain together - from APIs and FDF, to machinery, packaging, outsourcing and, biopharma– we enhance the industry’s ability to find new cost-effective solutions and learn about new developments that will sustain growth in the year ahead”.

Read More

Related news

Winners of the 16th Pharma Awards

Winners of the 16th Pharma Awards

11 Nov 2019

Companies and individuals from across the whole pharma supply chain recognised for their excellence and commitment.

Read more 
Sanofi opens its first digitally-enabled, continuous manufacturing facility

Sanofi opens its first digitally-enabled, continuous manufacturing facility

15 Oct 2019

One of the first digital manufacturing facilities in the world to use continuous, intensified biologics production technology.

Read more 
EC approves its first plant-derived cannabis-based medicine

EC approves its first plant-derived cannabis-based medicine

24 Sep 2019

Epidyolex (cannabidiol) approved for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.

Read more 
Integrating glucose sensing and insulin delivery technologies

Integrating glucose sensing and insulin delivery technologies

18 Sep 2019

Collaboration aims to provide a connected device experience for millions of people living with diabetes using insulin.

Read more 
Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

9 Sep 2019

Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.

Read more 
China relaxes import regulations to improve access and availability of affordable medicines

China relaxes import regulations to improve access and availability of affordable medicines

3 Sep 2019

The potential for generics to support the healthcare needs of China is significant.

Read more 
Exciting new vaccine targets killer disease TB

Exciting new vaccine targets killer disease TB

28 Aug 2019

Australian researchers produce early-stage vaccine which is inhaled into the lungs.

Read more 
Switzerland overtakes Germany as Europe’s biggest drug delivery innovator

Switzerland overtakes Germany as Europe’s biggest drug delivery innovator

16 Aug 2019

Pipeline of new drugs has helped drive increased innovation in packaging and drug delivery devices.

Read more 
How real-world data can revolutionise drug development

How real-world data can revolutionise drug development

9 Aug 2019

Utilising the current data environment and its data pools for the benefit of advancing research.

Read more 
Colorcon to incorporate TruTag's edible 'optical barcodes' in tablet film coatings

Colorcon to incorporate TruTag's edible 'optical barcodes' in tablet film coatings

6 Aug 2019

The benefits of this innovation include the ability to instantly and unequivocally authenticate products when suspect events.

Read more